CClinicalTrials.gg
CompletedNCT03791424Updated Jan 3, 2019

Changes of Skin Resistance After Midazolam and After the End of Anaesthesia

A Phase 4 interventional study of Midazolam in Anesthesia, sponsored by Charles University, Czech Republic. Completed at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-03.

Sponsored by Charles University, Czech Republic · Phase 4, Interventional, and Diagnostic

From the registry’s dates

  • Registered 3 years 11 months after the study started (first participant enrolled Oct 2014, registered Sep 2018).
Phase
Phase 4
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

It has been described that sympathetic activity, measured as changes in electrical skin resistance (SR), may be used to assess the adequacy of general anaesthesia. Our prospective study investigated how far measurements of skin resistance can help determine level of sedation. The secondary aim was to investigate if changes in skin resistance can be used for assessing recovery from anaesthesia.

Read the detailed description

Introduction Before anaesthesia, benzodiazepines are routinely used to reduce anxiety before anaesthesia and surgery. Usually anxiolysis is preferable to sedation, which may interfere with recovery after short procedures. Unfortunately, although anxiolytic sedatives are widely used in clinical practice, the methodology for assessing treatment effect of these compounds has not been well developed. Psychologic tests like the Hamilton Anxiety Rating Scale (HARS), the Wang Anxiety Rating Scale (WARS), or Zung Self-Rating Anxiety Scale (SAS) were used to assess changes in anxiety were developed for measuring effect of long-term therapy and are rather cumbersome and difficult to use in routine anaesthetic praxis.

More commonly used test in clinical perioperative use are the Ramsay sedation scale (RSS), the Richmond Agitation-Sedation Scale (RASS) and the Observer's Assessment of Alertness and Sedation scale (OAASS), but they focus mainly on level of sedation and not the level of anxiolysis. There are several reports demonstrating that there is a correlation between level of anxiety and changes in skin resistance.

Changes of skin resistance (SI) were first used in criminology in 1897 and in 1921 the method was used in criminology by August Larson together with changes of heart rate, respiratory rate and blood pressure for construction of polygraph. This method was many times validated and polygraph is still used as a "lie detector". More recently sever studies appeared demonstrating correlation between changes of skin resistance and sedation grade, bispectral index, reaction to stimulation, pain and motor activity.

The present double-blinded study was designed to refine methodology for objective evaluating effect of sedative and anxiolytic agents. The primary aim of our study was to examine if of changes in skin resistance after placebo pre-screening can be used for objective assessment of an anxiolytic effect of drugs compared to commonly used subjective scales like Ramsay sedation scale (RSS), or The Richmond Agitation-Sedation Scale (RASS) and Observer's Assessment of Alertness and Sedation scale(OAASS). The secondary aim was to evaluate if changes of skin resistance can be used for assessing recovery from anaesthesia.

Patients The study was performed in adult patients scheduled for knee arthroscopy or minor plastic surgery under general anaesthesia. Consent was obtained the day before surgery during pre-anaesthetic visit. Exclusion criteria were previous history of taking drugs affecting mental functions, history of psychic illness, implanted electrical device, know allergy to benzodiazepines, myasthenia gravis, ASA classification ASA 3 and more. All patients consented not to use any medication for sedation or anxiety, opioid analgesics, ethanol and illicit drugs 24 hours before surgery. Patients were instructed that they will be administered by a random order first sedative agent or placebo and will be observed for their level of sedation.

Measurements After arrival at the operating theatre, and venepuncture two standard AgCl ECG electrodes (Medico Electrodes International ltd.) size 32 mm x 52 mm (27x35) were attached to the palm side of the second and third finger of the non-dominating hand. Multimeter DM 3900 (Mastech) was used for measurements of SR. The device was controlled and approved for use in humans by the Department of Medical Biophysics and Informatics of the 3rd Medical Faculty of Charles University.

Observer's Assessment of Alertness and Sedation (OAAS) scale was used as a standard tool for measurements of sedation level at the same intervals as measurements of SR. The person providing OAAS assessment was blinded to the order of midazolam and placebo injection and only the anaesthetist administering both injections knew the order of drugs.

Data recording Ten min. rest break was given to participants in order that they adapt to the test situation. The rest value of SR was noticed and next all patients were administered placebo first and after 5 min period midazolam 2 mg i.v. After next 5 minutes patients were administered standard general anaesthesia with propofol, oxygen, nitrous oxide 60 % and isoflurane 1 MAC via laryngeal mask and sufentanil as needed. Monitoring was standard for this type of surgery (ECG, non-invasive blood pressure - NIBP, capnography and pulse oximetry). SR and OASS were recorded again after stop of volatile anaesthetic agent till opening eyes of the patient and obtaining verbal contact.

Statistical analysis SR values before placebo administration, 5 minutes after placebo, 5 minutes after midazolam, 5 min. after induction, at the end of surgery, 0 isoflurane level after anaesthesia with closed eyes and after eyes opening were recorded. Changes in SR values compared to baseline data were used for analyses by paired t-test. These relative changes enabled to compare only the course of changes independently of different absolute values. Pearson´s correlation coefficients were used to analyse relationship between OASS and SR values. P-value \< 0.05 was considered statistically significant.

The primary aim of our study was to assess if SR can be used as an objective measurement of level of sedation compared to much or less subjective OAAS. OASS was chosen because scoring was originally introduced to assess sedation with benzodiazepines, which was used in our study, too. The categories were responsiveness, speech, facial expression and eye appearance and each category was originally scored in 5 dimensions. The OAAS scale was found to have a high discriminatory power for the different levels of sedation (3), but may vary between observers. There is a limited number of methods for assessment onset and intensity of sedation. Commonly used Bispectral Index Score (BIS) monitoring is not dependent on a person and is used mainly during general anaesthesia. On the other hand the authors of a large meta-analysis concluded that its use for sedation in largely unreliable.

02

Conditions studied

  • Anesthesia

Keywords

  • sedation
  • midazolam
  • skin resistance
  • measurements
03

In context

Lead sponsor

Charles University, Czech Republic is the lead sponsor of 220 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • adult patients scheduled for knee arthroscopy or minor plastic surgery under general anaesthesia

Exclusion criteria

Exclusion Criteria:

  • previous history of taking drugs affecting mental functions, history of psychic illness, implanted electrical device, know allergy to benzodiazepines, myasthenia gravis, ASA classification ASA 3 and more. All patients consented not to use any medication for sedation or anxiety, opioid analgesics, ethanol and illicit drugs 24 hours before surgery.
05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Midazolam

    Midazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.

    Drug: Midazolam

  • Placebo comparator
    Control

    Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..

    Drug: Midazolam

Interventions

  • DrugMidazolam

    Administering premedication with sedative drug to relieve anxiety

    Also known as: Sedation

06

What researchers measure

Primary outcomes

  1. Changes of skin resistence (percent from base-line values measured in ohms) during sedation

    Investigation how far measurements of skin resistance can help determine level of sedation induced by intravenous midazolam

    Time frame: 10 min. before administration and 5 min. after administration of midazolam (total 15 min.)

Secondary outcomes

  1. Changes of skin resistence (percent from base-line values and values before termination of inhalational agent administration measured in ohms) during recovery from anaesthesia

    Investigation how far measurements of skin resistance can help determine level of recovery from general anaesthesia

    Time frame: From termination of inhalational agent administration till recovery to verbal comunication (expected time max. 15 min)

07

Study locations

1 site
  • University Hospital Kralovske Vinohrady
    Praha, 100 00, Czechia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03791424
Lead sponsor
Charles University, Czech Republic
Responsible party
Jiri Malek (Assoc. Prfo. Jiri Malek, CSc., Charles University, Czech Republic) — Principal investigator
First posted
Jan 2, 2019
Start date
Oct 1, 2014
Primary completion
Jun 26, 2015
Completion
Jun 26, 2015
Last update
Jan 3, 2019

Study contacts

Jiri Malek, M.D.
principal investigator · University Hospital Kralovske Vinohrady
Alice Kurzova, M.D.
study chair · University Hospital Kralovske Vinohrady

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion